Counterfeit bevacizumab and endophthalmitis

New England Journal of Medicine

Volumn 365, Issue 4, 2011, Pages 378-379

  Sun, Xiaodong ^a   Xu, Xun ^a   Zhang, Xi ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; COUNTERFEIT DRUG; GLUCOCORTICOID; RANIBIZUMAB;

ANTERIOR EYE CHAMBER; CHINA; DRUG INDUSTRY; DRUG PACKAGING; ENDOPHTHALMITIS; EPIDEMIC; EYE INFLAMMATION; HUMAN; HYPOPYON; LETTER; OFF LABEL DRUG USE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; VIAL; VITREOUS BODY;

EID: 79960885448     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1106415     Document Type: Letter

References (3)

1. Cheng J-W, Wei R-L. Ranibizumab for age-related macular degeneration. N Engl J Med 2011;364:582.
2. The CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
3. Rosenfeld PJ. Bevacizumab versus ranibizumab for AMD. N Engl J Med 2011;362:1966-7.